Isotechnika Reports Full Year and Fourth Quarter 2011 Financial Results
March 13, 2012 09:00 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, March 13, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) has released its financial results for the year and quarter ended December 31, 2011.
Financial...
Isotechnika Announces Agreement From the FDA on a Special Protocol Assessment for Its Phase 3 Voclosporin Trial
March 12, 2012 07:45 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, March 12, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) announced today that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special...
Isotechnika CEO to Present at BioPartnering North America 2012
February 27, 2012 08:15 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce that its CEO, Dr. Robert Foster, has been invited to...
Isotechnika Terminates Existing Agreement With ILJIN
January 31, 2012 08:15 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Consistent with prior communications from ILJIN, the company is pursuing discussions with ILJIN Life Science Co., Ltd. ("ILJIN") to potentially...
Isotechnika Announces Changes to Senior Management and Board of Directors
January 06, 2012 10:44 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Jan. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today a number of changes to its senior management and Board of...
Isotechnika Enters Into Development and Commercialization License Agreement With Vifor Pharma
January 03, 2012 08:45 ET
|
Aurinia Pharmaceuticals Inc.
EDMONTON, Alberta, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce that it has signed a Global Development and...